FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048574684> ?p ?o ?g. }

• W3048574684 endingPage "175883592092958" @default.
• W3048574684 startingPage "175883592092958" @default.
• W3048574684 abstract "Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. Histone-deacetylase inhibitors (HDACi) have shown activity in combination with chemotherapy in the treatment of solid tumors. Owing to its HDACi activity and its safe use for epileptic disorders, valproic acid (VPA) is a good candidate for anticancer therapy that we have largely explored preclinically translating our findings in currently ongoing clinical studies. We have shown in CRC models that HDACi, including VPA, induces synergistic antitumor effects in combination with fluoropyrimidines. Furthermore, unpublished results from our group demonstrated that VPA induces differentiation and sensitization of CRC stem cells to oxaliplatin. Moreover, preclinical and clinical data suggest that HDACi may prevent/reverse anti-angiogenic resistance.A randomized, open-label, two-arm, multicenter phase-II study will be performed to explore whether the addition of VPA to first line bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL) might improve progression-free survival (PFS) in RAS-mutated mCRC patients. A sample size of 200 patients was calculated under the hypothesis that the addition of VPA to chemotherapy/bevacizumab can improve PFS from 9 to 12 months, with one-sided alpha of 0.20 and a power of 0.80. Secondary endpoints are overall survival, objective response rate, metastases resection rate, toxicity, and quality of life. Moreover, the study will explore several prognostic and predictive biomarkers on blood samples, primary tumors, and on resected metastases.The Revolution study aims to improve the treatment efficacy of RAS-mutated mCRC through an attractive strategy evaluating the combination of VPA with standard cancer treatment. Correlative studies could identify novel biomarkers and could add new insight in the mechanism of interaction between VPA, fluoropyrimidine, oxaliplatin, and bevacizumab.EudraCT: 2018-001414-15; ClinicalTrials.gov identifier: NCT04310176." @default.
• W3048574684 created "2020-08-18" @default.
• W3048574684 creator A5001042648 @default.
• W3048574684 creator A5005851993 @default.
• W3048574684 creator A5006309105 @default.
• W3048574684 creator A5010799295 @default.
• W3048574684 creator A5010846929 @default.
• W3048574684 creator A5014792832 @default.
• W3048574684 creator A5015740152 @default.
• W3048574684 creator A5016966886 @default.
• W3048574684 creator A5019332793 @default.
• W3048574684 creator A5034347320 @default.
• W3048574684 creator A5035669120 @default.
• W3048574684 creator A5035710316 @default.
• W3048574684 creator A5035966506 @default.
• W3048574684 creator A5036337907 @default.
• W3048574684 creator A5036443897 @default.
• W3048574684 creator A5038665049 @default.
• W3048574684 creator A5041812067 @default.
• W3048574684 creator A5042758138 @default.
• W3048574684 creator A5048826974 @default.
• W3048574684 creator A5058691292 @default.
• W3048574684 creator A5062149201 @default.
• W3048574684 creator A5062538462 @default.
• W3048574684 creator A5063093846 @default.
• W3048574684 creator A5065270981 @default.
• W3048574684 creator A5067911315 @default.
• W3048574684 creator A5075134017 @default.
• W3048574684 creator A5085152226 @default.
• W3048574684 creator A5088304855 @default.
• W3048574684 creator A5091003529 @default.
• W3048574684 date "2020-01-01" @default.
• W3048574684 modified "2023-10-16" @default.
• W3048574684 title "Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with<i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocol" @default.
• W3048574684 cites W1546107639 @default.
• W3048574684 cites W1907650756 @default.
• W3048574684 cites W1914351667 @default.
• W3048574684 cites W1968293348 @default.
• W3048574684 cites W1977468182 @default.
• W3048574684 cites W1980626135 @default.
• W3048574684 cites W1984025642 @default.
• W3048574684 cites W1986098515 @default.
• W3048574684 cites W1987017438 @default.
• W3048574684 cites W1988300276 @default.
• W3048574684 cites W2001710904 @default.
• W3048574684 cites W2003221870 @default.
• W3048574684 cites W2008650297 @default.
• W3048574684 cites W2025466972 @default.
• W3048574684 cites W2027346433 @default.
• W3048574684 cites W2042506499 @default.
• W3048574684 cites W2048565648 @default.
• W3048574684 cites W2056835378 @default.
• W3048574684 cites W2071888464 @default.
• W3048574684 cites W2071934663 @default.
• W3048574684 cites W2074976119 @default.
• W3048574684 cites W2079101776 @default.
• W3048574684 cites W2082804884 @default.
• W3048574684 cites W2104425103 @default.
• W3048574684 cites W2106357158 @default.
• W3048574684 cites W2111013340 @default.
• W3048574684 cites W2111715042 @default.
• W3048574684 cites W2115316179 @default.
• W3048574684 cites W2131292583 @default.
• W3048574684 cites W2134459196 @default.
• W3048574684 cites W2136103407 @default.
• W3048574684 cites W2138937001 @default.
• W3048574684 cites W2139771301 @default.
• W3048574684 cites W2142233318 @default.
• W3048574684 cites W2149379768 @default.
• W3048574684 cites W2152936144 @default.
• W3048574684 cites W2159353124 @default.
• W3048574684 cites W2164124988 @default.
• W3048574684 cites W2164382188 @default.
• W3048574684 cites W2166628771 @default.
• W3048574684 cites W2167292948 @default.
• W3048574684 cites W2167571044 @default.
• W3048574684 cites W2170601050 @default.
• W3048574684 cites W2170926194 @default.
• W3048574684 cites W2171185186 @default.
• W3048574684 cites W2228444494 @default.
• W3048574684 cites W2234514144 @default.
• W3048574684 cites W2245684467 @default.
• W3048574684 cites W2272438203 @default.
• W3048574684 cites W2273538304 @default.
• W3048574684 cites W2284683492 @default.
• W3048574684 cites W2288225021 @default.
• W3048574684 cites W2290460030 @default.
• W3048574684 cites W2299919100 @default.
• W3048574684 cites W2302716119 @default.
• W3048574684 cites W2394893668 @default.
• W3048574684 cites W2401136278 @default.
• W3048574684 cites W2465450966 @default.
• W3048574684 cites W2470575266 @default.
• W3048574684 cites W2530525132 @default.
• W3048574684 cites W2535558810 @default.
• W3048574684 cites W2566090298 @default.
• W3048574684 cites W2588170076 @default.
• W3048574684 cites W2589656556 @default.

• next